{
    "id": 27993,
    "fullName": "RB1 E268*",
    "impact": "nonsense",
    "proteinEffect": "loss of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "RB1 E268* results in a premature truncation of the Rb1 protein within domain A at amino acid 268 of 928 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), E268* is predicted to lead to a loss of Rb1 protein function.",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5925,
        "geneSymbol": "RB1",
        "terms": [
            "RB1",
            "OSRC",
            "p105-Rb",
            "p110-RB1",
            "pp110",
            "PPP1R130",
            "pRb",
            "RB"
        ]
    },
    "variant": "E268*",
    "createDate": "05/01/2018",
    "updateDate": "03/20/2019",
    "referenceTranscriptCoordinates": {
        "id": 147549,
        "transcript": "NM_000321",
        "gDna": "chr13:g.48362898G>T",
        "cDna": "c.802G>T",
        "protein": "p.E268*",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 13827,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, RB1 mutations including E268*, I101fs, T738_R775del, and V654fs were identified in the circulating tumor DNA of a patient with estrogen receptor positive, progesterone receptor positive, and Erbb2 (Her2)-negative, invasive ductal carcinoma at the time of disease progression after 8 months of Ibrance (palbociclib) and Faslodex (fulvestrant) combination treatment (PMID: 29236940).",
            "molecularProfile": {
                "id": 29570,
                "profileName": "RB1 I101fs RB1 E268* RB1 V654fs RB1 T738_R775del"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11295,
                    "pubMedId": 29236940,
                    "title": "Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29236940"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 29563,
            "profileName": "RB1 E268*",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29570,
            "profileName": "RB1 I101fs RB1 E268* RB1 V654fs RB1 T738_R775del",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 147549,
            "transcript": "NM_000321",
            "gDna": "chr13:g.48362898G>T",
            "cDna": "c.802G>T",
            "protein": "p.E268*",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}